BTIG Cuts Keryx Biopharmaceuticals (KERX) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Roth Capital Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
August 10, 2015 6:49 AM EDTRoth Capital downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Buy to Neutral with a price target of $6.00 (from $11.00) following Q2 results, citing too much hedging.
Analyst Joseph Pantginis commented, "Following 2Q15 results, we believe Auryxia's headwinds are strong at the moment and step to the... More
Keryx Biopharma (KERX) Reports In-Line Q2 EPS
August 5, 2015 7:17 AM EDTKeryx Biopharma (NASDAQ: KERX) reported Q2 EPS of ($0.26), in-line with the analyst estimate of ($0.26). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $2.86 million.
"We are making progress on several important milestones across our business, including securing broad reimbursement for Auryxia (ferric citrate) that today enables... More
